How India Exports Loratadine to the World

In the United States, loratadine is approved for over-the-counter (OTC) use, reflecting its established safety and efficacy profile. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for loratadine, indicating a competitive generic market. For instance, Andrx Pharmaceuticals received approval for an ANDA (No. 075706) for loratadine and pseudoephedrine sulfate on February 21, 2003. Additionally, Taro Pharmaceuticals Inc. obtained approval for loratadine oral suspension (NDA No. 021734) on October 4, 2005. The absence of import alerts or significant regulatory actions against loratadine underscores its compliance with U.S. regulatory standards. Given that 9.2% of India's loratadine exports are directed to the U.S., the presence of 347 active Indian exporters highlights the importance of adhering to FDA regulations to maintain market access.

Within the European Union, loratadine is subject to marketing authorization by national competent authorities. The European Medicines Agency (EMA) has evaluated loratadine-containing products, such as Loratadine Sandoz 10, which underwent an Article 29 referral due to concerns over bioequivalence. The Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits did not outweigh the risks, leading to a suspension of the marketing authorization in the Netherlands in August 2009. (ema.europa.eu) This underscores the necessity for exporters to ensure bioequivalence and compliance with EU Good Manufacturing Practice (GMP) standards. In the United Kingdom, post-Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization of medicinal products, maintaining stringent requirements for safety, efficacy, and quality.

Loratadine is included in the World Health Organization's (WHO) Model List of Essential Medicines, recognizing its importance in a basic health system. This inclusion facilitates its adoption in national formularies and underscores its therapeutic significance. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is crucial for ensuring product quality and acceptance in global markets.

In India, loratadine is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, loratadine is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the quality of pharmaceutical exports.

The primary patents for loratadine have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has resulted in widespread availability and cost-effective options for consumers globally.

In June 2025, the NPPA conducted a review of antihistamine pricing, including loratadine, to assess market trends and ensure affordability. Although no immediate price controls were implemented, the review highlighted the need for ongoing monitoring. In September 2025, the CDSCO issued updated guidelines for bioequivalence studies, emphasizing stricter compliance for generic antihistamines to align with international standards. In December 2025, the EMA initiated a pharmacovigilance review of second-generation antihistamines, including loratadine, to evaluate long-term safety data, with findings expected to influence future regulatory decisions.

These developments underscore the dynamic regulatory environment surrounding loratadine, necessitating continuous vigilance and compliance from manufacturers and exporters to maintain market access and ensure patient safety.

India's pharmaceutical industry, while a global leader in generic drug production, remains heavily reliant on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) manufacturing. This dependency is significant, with approximately 60–70% of KSMs imported from China. Such reliance exposes the supply chain to vulnerabilities, particularly when disruptions occur in Chinese manufacturing. For instance, in September 2025, China reduced prices of 41 APIs and KSMs by 40–50%, impacting the competitiveness of Indian API manufacturers.

The COVID-19 pandemic further highlighted these risks. In early 2020, factory shutdowns in China led to shortages of critical APIs, causing price surges and production delays in India. This situation underscored the need for India to bolster its domestic production capabilities to mitigate future supply chain disruptions.

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in Loratadine exports from India. The top five exporters account for 76.4% of total exports, with SANDOZ PRIVATE LIMITED alone contributing 60.7% ($105.1M USD). This concentration poses a significant single-source risk, as any operational issues within these key suppliers could disrupt the entire supply chain.

To address such vulnerabilities, the Indian government introduced the Production Linked Incentive (PLI) scheme in February 2021, aiming to reduce import dependence on KSMs and APIs. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, marking a step towards self-reliance.

Geopolitical tensions have further complicated the pharmaceutical supply chain. In February 2026, Iran initiated a partial closure of the Strait of Hormuz, a vital maritime route, affecting global oil supplies and increasing shipping costs. Such disruptions can delay shipments of essential raw materials and APIs, leading to production bottlenecks.

Additionally, the U.S. Food and Drug Administration (FDA) has issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP). In February 2025, India's Global Calcium and China's Wuhu Nuowei Chemistry faced such warnings, highlighting ongoing quality concerns and the risks associated with regulatory non-compliance.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical APIs and KSMs to build a more resilient supply chain.

• Strengthen Quality Controls: Implement rigorous quality assurance protocols to ensure compliance with international standards and avoid regulatory sanctions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact supply chains and develop contingency plans accordingly.

• Leverage Government Incentives: Utilize schemes like the PLI to support infrastructure development and reduce reliance on imports.

RISK_LEVEL: HIGH